Baloh, Carolyn H. http://orcid.org/0000-0003-4939-7160
Borkar, Samiksha A. http://orcid.org/0000-0002-6290-1088
Chang, Kai-Fen http://orcid.org/0000-0003-3893-7176
Yao, Jiqiang
Hershfield, Michael S. http://orcid.org/0000-0003-3589-8554
Parikh, Suhag H. http://orcid.org/0000-0002-6066-9852
Kohn, Donald B. http://orcid.org/0000-0003-1840-6087
Goodenow, Maureen M. http://orcid.org/0000-0002-4750-9627
Sleasman, John W. http://orcid.org/0000-0003-0078-5867
Funding for this research was provided by:
National Institute of Allergy and Infectious Diseases (R01 AI1001471, UO1 AI100801, AI007062-38)
National Human Genome Research Institute (HG008955-01A1)
Article History
Received: 14 November 2020
Accepted: 5 April 2021
First Online: 28 June 2021
Declarations
:
: All study participants were enrolled with approvals by the Institutional Review Boards of the University of South Florida and Duke University.
: Written informed consents were obtained from all participants or parents including the parents of the ADA-deficient child. Additional consent for publication of case report was obtained from the parents of the ADA-deficient child.
: All authors provided consent for publication.
: MH receives funding support from Leadiant Biosciences and Orchard Therapeutics.DK is an inventor on lentiviral gene therapy for ADA SCID licensed by the UC Regents to Orchard Therapeutics and serves as a member of the Orchard Scientific Advisory Board.The other authors (CHB, SB, KC, JY, SP, MG, JS, LY) declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.